

Date: 10th of February 2014
Venue: Lecture Hall

The 8th Leading Seminar

Adipokines - from discovery to therapeutic development

Lecturer: Dr. Yu Wang

Department of Pharmacology and Pharmacy,
LKS Faculty of Medicine, The University of Hong Kong,
Hong Kong SAR, China
E mail: yuwanghk@hku.hk



Abstract

Over a quarter of the world's population is overweight and obese, which directly cause the high prevalence of chronic diseases such as type 2 diabetes, cardiovascular dysfunction and life style-related cancers. Abnormalities in adipose tissue and the aberrant production of adipokines from adipocytes are the major culprits for obesity-related medical complications. Our laboratory has applied a highly integrated approach to identify novel adipokines and investigate their roles in various pathophysiological conditions. Here, the beneficial and harmful functions of two adipokines [adiponectin and lipocalin-2] in the development of obesity-related cardiometabolic syndrome will be presented and discussed.

Time Schedule:

15:00 – 16:30 Lecture at Lecture Hall

16:45 – 17:45 Discussion at Conference Room

Biography

Name: Yu Wang

Associate Professor
Department of Pharmacology and Pharmacy
LKS Faculty of Medicine
The University of Hong Kong (HKU)



ACADEMIC DEGREES:

MBChB	1992	Anhui Medical University (Medicine)
M.Sc.	1999	University of Auckland (Biochemistry and Proteomics)
Ph.D.	2003	University of Auckland (Biomedical Sciences and Proteomics)

PROFESSIONAL APPOINTMENTS:

2013 -	Associated Professor, Department of Pharmacology and Pharmacy, HKU
2008 - 2013	Assistant Professor, Department of Pharmacology and Pharmacy and Institute of Molecular Technology for Drug Discovery and Synthesis, HKU
2004 - 2008	Research Assistant Professor, Genome Research Center & Department of Biochemistry, HKU
2003 - 2004	Research Fellow, Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, New Zealand

RESEARCH INTERESTS:

My research is focusing on obesity- and ageing-related cardiometabolic diseases. During the past 10 years, a discovery pipeline using “Omics” approaches has been successfully established in our laboratory for identification and characterization of a number of adipokines, including adiponectin and lipocalin-2. Using genetically modified animal models and samples from clinical patients, the therapeutic values of these adipokines have been thoroughly studied and validated, including the hepatoprotective functions of adiponectin and the anti-hypertensive potentials of lipocalin-2 inhibitors. In addition, we have established various research platforms for SIRT1, a longevity regulator, and elucidated its therapeutic potential in ageing-related cardiovascular diseases. For more details, please visit <http://www.pharma.hku.hk/pharma/staffweb/DrYuWang/index.php>